Kura Oncology, Inc.
KURA$1.60B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO192 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Oct 22, 2026
29wMarket Overview
Stock performance and key metrics
KURA News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
Ziftomenib
Acute Myeloid Leukemia (AML)
Tipifarnib
HNSCC
Midazolam
Advanced Malignant Neoplasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ziftomenib | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
Tipifarnib | Phase 2 | HNSCC | - | - |
Midazolam | Phase 2 | Advanced Malignant Neoplasm | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply